THU0450 OPTIMISTIC STATUS ASSOCIATES WITH COMPLIANCE TO URATE-LOWERING THERAPY IN GOUT PATIENTS

Treatment approaches and adherence to urate-lowering therapy for patients with gout

Gout is the most common inflammatory arthritis characterized by painful disabling acute attacks. It is caused by hyperuricemia and deposition of urate crystals in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis with joint damage, tophi formation and urate nephropathy. Gout is associated with significant morbidity and health care associated cost. The go...

Adherence with urate-lowering therapies for the treatment of gout

INTRODUCTION Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout. METHODS We identified persons using two integrated delivery systems aged 18 years or older with a diagnosis of gout who initiated use of allopurinol, probenecid or sulfinpyrazone from 1 January...

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout

BACKGROUND To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout. METHODS Fourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate (Lipidil Supra 160 mg/d). Patients were stable on urate lowering agents (allopurinol or benzbroma...

Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England.

Eligibility for and Prescription of Urate-Lowering Treatment in PatientsWith Incident Gout in England Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommenduratelowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnos...

Profound Urate-Lowering May Reduce Joint Damage in Tophaceous Gout